Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation

Transplant International

Volumn 27, Issue 3, 2014, Pages 271-279

  Longuet, Hélène ^a   Sautenet, Bénédicte ^a   Gatault, Philippe ^a,b   Thibault, Gilles ^a,c   Barbet, Christelle ^a   Marliere, Jean Frédérique ^a   Halimi, Jean Michel ^a,b   Lebranchu, Yvon ^a,b   Baron, Christophe ^a,b   Büchler, Matthias ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b FHU SUPORT   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

immunosuppression; kidney transplantation; lymphocytes; risk factors

Indexed keywords

BASILIXIMAB; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CD4+ T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTIONS; PROCEDURES; RABBIT; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTIONS; RABBITS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84894066686     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12249     Document Type: Article

References (31)

1. Meier-Kriesche HU, Arndorfer JA, Kaplan B,. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769.
2. Thibaudin D, Alamartine E, Mariat C, Absi L, Berthoux F,. Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 2005; 80: 1514.
3. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B,. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227.
4. Ducloux D, Carron PL, Motte G, et al,. Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transpl Int 2002; 15: 393.
5. Gurkan S, Luan Y, Dhillon N, et al,. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10: 2132.
6. Pearl JP, Parris J, Hale DA, et al,. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
7. Glowacki F, Al Morabiti M, Lionet A, et al,. Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies. Transplant Proc 2009; 41: 3323.
8. Ducloux D, Courivaud C, Bamoulid J, et al,. Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol 2010; 21: 868.
9. Klaus G, Mostert K, Reckzeh B, Mueller TF,. Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion. Transplantation 2003; 76: 1719.
10. Ducloux D, Bamoulid J, Courivaud C, et al,. Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transpl Immunol 2011; 25: 56.
11. Buchler M, Caillard S, Barbier S, et al,., SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
12. Glück T, Geerdes-Fenge HF, Straub RH, et al,. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000; 28: 227.
13. Gill PS,. A robust mixed linear model analysis for longitudinal data. Stat Med 2000; 19: 975.
14. Taylor JM, Law N,. Does the covariance structure matter in longitudinal modelling for the prediction of future CD4 counts? Stat Med 1998; 17: 2381.
15. Smith DK, Neal JJ, Holmberg SD,. Unexplained opportunistic infections and CD4 + T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4 + T-lymphocytopenia Task Force. N Engl J Med 1993; 328: 373.
16. Ducloux D, Carron PL, Racadot E, et al,. CD4 lymphocytopenia in long-term renal transplant recipients. Transplant Proc 1998; 30: 2859.
17. Ducloux D, Carron PL, Rebibou JM, et al,. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65: 1270.
18. Ducloux D, Challier B, Saas P, Tiberghien P, Chalopin JM,. CD4 cell lymphopenia and atherosclerosis in renal transplant recipients. J Am Soc Nephrol 2003; 14: 767.
19. Fujimaki K, Maruta A, Yoshida M, et al,. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 27: 1275.
20. Williams KM, Hakim FT, Gress RE,. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007; 19: 318.
21. Roux E, Dumont-Girard F, Starobinski M, et al,. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000; 96: 2299.
22. Weiskopf D, Weinberger B, Grubeck-Loebenstein B,. The aging of the immune system. Transpl Int 2009; 22: 1041.
23. Chen J, Iannone MA, Li MS, et al,. A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension. Genome Res 2000; 10: 549.
24. Girndt M, Sester U, Sester M, Kaul H, Kohler H,. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14: 2807.
25. Raska K Jr, Raskova J, Shea SM, et al,. T cell subsets and cellular immunity in end-stage renal disease. Am J Med 1983; 75: 734.
26. Yoon JW, Gollapudi S, Pahl MV, Vaziri ND,. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006; 70: 371.
27. Vacher-Coponat H, Brunet C, Moal V, et al,. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. Transplantation 2006; 82: 558.
28. Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y,. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003; 17: 539.
29. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR,. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3 + lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73: 1514.
30. Wong W, Agrawal N, Pascual M, et al,. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006; 19: 629.
31. Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W,. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol 2012; 26: 186.